Your session is about to expire
← Back to Search
Oral Atogepant Tablets for Migraine (Kaleidoscope Trial)
Kaleidoscope Trial Summary
This trial studies a medicine, atogepant, to see how safe and effective it is in children (ages 6-17) with episodic migraine headaches. Participants will be randomized to receive placebo, low or high doses of the medicine for 12 weeks.
Kaleidoscope Trial Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowKaleidoscope Trial Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Kaleidoscope Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I have had specific severe migraines, as defined by a 2018 standard.I am between 6 to 11 years old and need preventive treatment for my migraines.I have been diagnosed with a specific type of severe headache or facial pain.My weight is between 44 lbs and 298 lbs.I experience 4 to 14 migraine days and less than 15 headache days in a month.I have been diagnosed with chronic migraines.I have been diagnosed with migraines, with or without aura, for at least 6 months.I've been hospitalized for migraine 3+ times in the last 6 months.
- Group 1: Double-Blind Treatment Period: Low Dose Atogepant (12-17 yrs)
- Group 2: Open-Label PK Substudy: Atogepant Dose A (6-11 yrs)
- Group 3: Open-Label PK Substudy: Atogepant Dose B (6-11 yrs)
- Group 4: Double-Blind Treatment Period: Low Dose Atogepant (6-11 yrs)
- Group 5: Double-Blind Treatment Period: High Dose Atogepant (6-11 yrs)
- Group 6: Double-Blind Treatment Period: Placebo (12-17 yrs)
- Group 7: Double-Blind Treatment Period: High Dose Atogepant (12-17 yrs)
- Group 8: Double-Blind Treatment Period: Placebo (6-11 yrs)
- Pivotal Trial - The final step before approval, pivotal trials feature drugs that have already shown basic safety & efficacy.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Does this clinical trial include any participants of advanced age?
"The study seeks to enrol participants who are six years old or older, but not yet 17."
How many geographic areas have been selected to host this research endeavor?
"This trial is taking place in 45 different medical centres, ranging from Little Rock to Lafayette and Anaheim. To reduce potential travel burdens, it would be most sensible for patients to participate at the site nearest them."
Has the Federal Drug Administration (FDA) sanctioned Open-Label PK Substudy: Atogepant Dose A (6-11 yrs)?
"This Phase 3 trial has accumulated sufficient evidence to rate the safety of Open-Label PK Substudy: Atogepant Dose A (6-11 yrs) as a 3."
Does this medical experiment have any openings for participants?
"Data housed on clinicaltrials.gov indicates that this particular trial, which was originally posted in February of 2023 and last updated at the end of January, is no longer seeking participants. However, 159 other medical studies are actively recruiting patients currently."
What prerequisites must individuals meet to be eligible for enrollment in this clinical trial?
"This clinical trial seeks 450 kids aged 6 to 17 who suffer from migraine with aura. Applicants must weigh between 44 lbs and 298 lbs, have a history of episodic migraines (in accordance with the International Classification of Headache Disorders), experience 4-14 migraine days in a 28 day period according to their eDiary, and be eligible for preventive treatment (for those interested in participating in the PK substudy)."
Who else is applying?
What state do they live in?
What site did they apply to?
What portion of applicants met pre-screening criteria?
Why did patients apply to this trial?
Share this study with friends
Copy Link
Messenger